IGN 002

Drug Profile

IGN 002

Alternative Names: Anti-CD20 monoclonal antibody+IFN (IGN002); IGN-002

Latest Information Update: 12 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunGene
  • Developer ImmunGene; The Leukemia & Lymphoma Society; Valor Biotherapeutics
  • Class Antineoplastics; Cytokines; Monoclonal antibodies; Proteins
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 02 May 2017 ImmunGene acquires IGN 002 from Valor Biotherapeutics
  • 27 Jul 2016 Valor Biotherapeutics, The Leukemia and Lymphoma Society and ImmuGene plan a phase II extension trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT02847949)
  • 01 Dec 2015 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT02519270)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top